NCT02720536View on ClinicalTrials.gov

Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation

PHASE3CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

August 16, 2016

Primary Completion Date

July 23, 2019

Study Completion Date

July 23, 2019

Conditions
Chronic Iron Overload
Interventions
DRUG

Deferasirox

Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.

Trial Locations (14)

1140

Novartis Investigative Site, Vienna

16128

Novartis Investigative Site, Genova

20122

Novartis Investigative Site, Milan

37126

Novartis Investigative Site, Verona

44100

Novartis Investigative Site, Cona

54642

Novartis Investigative Site, Thessaloniki

73100

Novartis Investigative Site, Lecce

80138

Novartis Investigative Site, Napoli

90127

Novartis Investigative Site, Palermo

90146

Novartis Investigative Site, Palermo

95125

Novartis Investigative Site, Catania

115 27

Novartis Investigative Site, Goudi-Athens

265 00

Novartis Investigative Site, Pátrai

09121

Novartis Investigative Site, Cagliari

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY